Emerson Clinical Research Institute | Falls Church, VA

Research site

(Unclaimed)

Location

410 S. Washington Street, Falls Church, Virginia, United States of America

Site insights

Top conditions

Top treatments

Netarsudil

APL-2

Bimatoprost

Pegcetacoplan

Povidone

Timolol Maleate

CBT-001

Apraclonidine Hydrochloride

Faricimab

Iodine

Parent organization

This site is a part of Emerson Clinical Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 16 total trials

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle i...

Enrolling

Pterygium

Drug: CBT-001

Drug: Vehicle

A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in...

Enrolling

Ocular Redness

Drug: Apraclonidine Hydrochloride Ophthalmic Solution

Drug: Vehicle

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

Active, not recruiting

Age Related Macular Degeneration

Drug: HLX04-O

Drug: ranibizumab

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting

Glaucoma

Ocular Hypertension

Drug: Rhopressa®

Drug: T4090 0.3%

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hyper...

Invitation-only

Open-Angle Glaucoma

Ocular Hypertension

Drug: Bimatoprost SR

Other: Standard of Care

Locations recently updated

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling

Age Related Macular Degeneration (ARMD)

Drug: Elamipretide

Drug: Placebo